A5114888754- HER2/EGFR in Cancer Research
- Breast Cancer Treatment Studies
- AI in cancer detection
- Monoclonal and Polyclonal Antibodies Research
- Cancer Genomics and Diagnostics
- Estrogen and related hormone effects
- Molecular Biology Techniques and Applications
- Radiomics and Machine Learning in Medical Imaging
- Bone health and treatments
- Gene expression and cancer classification
- RNA and protein synthesis mechanisms
- Gastric Cancer Management and Outcomes
- Advanced Biosensing Techniques and Applications
- Bone Metabolism and Diseases
- Clinical Laboratory Practices and Quality Control
- Cutaneous Melanoma Detection and Management
- Sarcoma Diagnosis and Treatment
- RNA Research and Splicing
- RNA modifications and cancer
- Genomics and Chromatin Dynamics
- Genetic factors in colorectal cancer
- Vascular Malformations and Hemangiomas
- Soil Mechanics and Vehicle Dynamics
- Vitamin D Research Studies
- Genetics, Bioinformatics, and Biomedical Research
Melbourne Genomics Health Alliance
2015-2025
Royal College of Pathologists of Australasia
2011-2017
Canadiana.org
2017
University Health Network
2016-2017
The University of Queensland
2011-2016
Griffith University
2011-2016
University of Toronto
2016
Princess Alexandra Hospital
2006-2015
Queensland University of Technology
2005-2014
Royal Brisbane and Women's Hospital
2011-2014
To develop a guideline to improve the accuracy of immunohistochemical (IHC) estrogen receptor (ER) and progesterone (PgR) testing in breast cancer utility these receptors as predictive markers.
Abstract Purpose.—To develop a guideline to improve the accuracy of immunohistochemical (IHC) estrogen receptor (ER) and progesterone (PgR) testing in breast cancer utility these receptors as predictive markers. Methods.—The American Society Clinical Oncology College Pathologists convened an international Expert Panel that conducted systematic review evaluation literature partnership with Cancer Care Ontario developed recommendations for optimal IHC ER/PgR performance. Results.—Up 20%...
Epigenetic alterations in the cancer methylome are common breast and provide novel options for tumour stratification. Here, we perform whole-genome methylation capture sequencing on small amounts of DNA isolated from formalin-fixed, paraffin-embedded tissue triple-negative (TNBC) matched normal samples. We identify differentially methylated regions (DMRs) enriched with promoters associated transcription factor binding sites hypersensitive sites. Importantly, stratify TNBCs into three...
Primary intraosseous rhabdomyosarcomas (RMSs) are extremely rare. Recently 2 studies reported 4 cases of primary RMS with EWSR1/FUS-TFCP2 gene fusions, associated somewhat conflicting histologic features, ranging from spindle to epithelioid. In this study we sought further investigate the pathologic and molecular abnormalities a larger group RMSs by combined approach using targeted RNA sequencing analysis fluorescence in situ hybridization (FISH). We identified 7 cases, 3 males females, all...
Standardization of controls, both positive and negative is needed for diagnostic immunohistochemistry (dIHC). The use IHC-negative irrespective type, although well established, not standardized. As such, the relevance applicability controls continues to challenge pathologists laboratory budgets. Despite clear theoretical notion that appropriate serve demonstrate sensitivity specificity dIHC test, it remains unclear which types are applicable and/or useful in day-to-day clinical practice....
Estrogen receptor (ER)-negative breast cancer is heterogeneous, and the biology of this disease has remained poorly understood. Molecular apocrine a subtype ER-negative that characterized by overexpression steroid-response genes such as AR high rate ErbB2 amplification. In study, we have identified positive feedback loop between extracellular signal-regulated kinase (ERK) signaling pathways in molecular cancer. process, regulates ERK phosphorylation activity. addition, inhibition results...
MicroRNAs (miRNAs) are small non-coding RNAs of ∼20 nt in length that capable modulating gene expression post-transcriptionally. Although miRNAs have been implicated cancer, including breast the regulation miRNA transcription and role defects this process cancer is not well understood. In study we mapped promoters 93 cancer-associated miRNAs, then looked for associations between DNA methylation 15 these cells. The with clearest association included a previously described novel promoter...
While oestrogen, progesterone and growth factors, including hormone (GH), are clearly implicated in the pathogenesis of breast cancer, there is now evidence that newly described ghrelin axis also involved. The aims this study were to investigate expression cancer tissues cell lines examine effect on proliferation vitro. Ghrelin its functional receptor, secretagogue receptor (GHSR) type 1a, expressed normal tissue specimens lines. In contrast, truncated GHSR 1b isoform was exclusively...
Breast cancer outcome, including response to therapy, risk of metastasis and survival, is difficult predict using currently available methods, highlighting the urgent need for more informative biomarkers. Androgen receptor (AR) has been implicated in breast carcinogenesis however its potential be an biomarker yet fully explored. In this study, AR protein levels were determined a cohort 73 Grade III invasive ductal adenocarcinomas.The tumour samples was by immunohistochemistry results...
Validation of immunohistochemistry (IHC) assays is a subject that great importance to clinical practice as well basic research and trials. When applied focused on patient safety, validation IHC creates objective evidence used for care are "fit-for-purpose." needs be properly informed by modeled assess the purpose assay, which will further determine what sphere required, scope, type, tier technical validation. These concepts defined in this review, part 3 4-part series "Evolution Quality...
Technical progress in immunohistochemistry (IHC) as well the increased utility of IHC for biomarker testing precision medicine avails us opportunity to reassess clinical a laboratory test and its proper characterization special type immunoassay. IHC, used current applications, is descriptive, qualitative, cell-based, usually nonlinear, situ protein immunoassay, which readout results principally performed by pathologists rather than instruments on immunoassay performed. This modus operandi...
ABSTRACT We describe the phenotypic and genotypic spectrum of patients with vascular anomaly (VA) in a paediatric multi‐disciplinary VA clinic. measured clinical utility genotyping by comparing pre posttest diagnosis management. A 46‐month retrospective analysis occurred for 250 offered genetic testing DNA was extracted from biopsied lesions. The coding regions 27 genes were amplified multiplex PCR sequenced mean coverage depth ranging 3005× to 66,320×, achieving >95% amplification at...
Log in or Register Subscribe to journalSubscribe Get new issue alertsGet alerts Enter your Email address: Wolters Kluwer Health may email you for journal and information, but is committed maintaining privacy will not share personal information without express consent. For more please refer our Privacy Policy. eTOC Secondary Logo Journal All Articles Images Videos Podcasts Blogs Advanced Search Toggle navigation Login & Issues Current IssuePrevious IssuesPublished Ahead-of-Print Authors...
Abstract While the etiology of breast cancer remains enigmatic, some recent reports have examined role human papillomavirus (HPV) in carcinogenesis. The purpose this study was to determine prevalence HPV tissue using PCR analysis and sequencing. Fifty‐four (54) fresh frozen cancers samples that were removed from a cohort patients analyzed. Samples tested for comprehensive primers, situ hybridization performed on paraffin embedded sections. Findings correlated with clinical pathological...
Trastuzumab provides a survival benefit in patients with human epidermal growth factor receptor 2 (HER2)-amplified/overexpressed advanced gastric and gastroesophageal junction cancers (GC/GJCs). However, the optimal method for testing is unclear. The aim of this study was to assess interlaboratory agreement on HER2 scoring GC/GJC aid development robust algorithm diagnostic practice Australia. Nine laboratories assessed status 100 tissue samples by immunohistochemistry (IHC) situ...
The numbers of diagnostic, prognostic, and predictive immunohistochemistry (IHC) tests are increasing; the implementation validation new IHC tests, revalidation existing as well on-going need for daily quality assurance monitoring present significant challenges to clinical laboratories. There is a proper tools, specifically tissue tools that will enable laboratories successfully carry out these processes. This paper clarifies, through lens laboratory how validation, verification, can be...
Background and Aims: Immunohistochemistry (IHC) has replaced radioligand binding assay for the determination of oestrogen receptor (ER) status in breast carcinoma. IHC is also used assessment progesterone (PR) HER2. The Royal College Pathologists Australasia (RCPA) Quality Assurance Program (QAP) introduced a markers module 2003 to evaluate performance laboratories with ER, PR Methods: An audit reporting carcinomas was performed 2005 2006 in-house results. Laboratories were asked submit...
Abstract BRCA1 is a breast cancer susceptibility gene that down-regulated in significant proportion of sporadic cancers. posttranscriptionally regulated by RNA-binding proteins, the identities which are unknown. HuR an RNA binding protein implicated posttranscriptional regulation many genes and overexpressed cancer. To investigate possibility these two molecules functionally linked cancer, we performed bioinformatic analysis 3′ untranslated region (UTR), RNA-protein assays with 3′UTR,...
In August 2006, the Australian government approved subsidized trastuzumab therapy for human epidermal growth factor receptor 2 (HER2)-positive early breast cancer, and it was mandated that HER2 testing should be performed using in situ hybridization (ISH) rather than immunohistochemistry (IHC). Here we review results of first regulated, nationwide program to provide ISH all newly diagnosed cancer patients, with a particular emphasis on cases where IHC were discordant. Data from laboratories...